抗雄激素药物治疗皮肤病研究进展

doi:10.35541/cjd.20210024

Abstract

Abstract: 【Abstract】 Androgens are important sex hormones in the body, and are involved in the occurrence and development of various skin diseases, such as acne, androgenetic alopecia, hirsutism. Anti-androgen drugs can act on different sites in the androgen synthesis and functional pathways to antagonize the effects of androgens, and can be used in the alleviation and treatment of related diseases. In recent years, some research progress has been made in the treatment of skin diseases with anti-androgen drugs. For example, clascoterone is a first-in-class topical drug in the treatment of acne in the last 40 years, dutasteride can be applied in male patients aged over 20 years with androgenetic alopecia, and topical finasteride is markedly effective for the treatment of androgenetic alopecia, as well as idiopathic hirsutism in females. This review summarizes research progress in anti-androgen drugs in the treatment of skin diseases in recent years.

Key words: Androgen antagonists, Skin diseases, Therapy, Alopecia, Hirsutism, Acne

Sun Xiaojie, Liu Yi. Anti-androgen drugs in the treatment of skin diseases[J]. Chinese Journal of Dermatology, 2023, 56(9): 882-885.doi:10.35541/cjd.20210024

References ［31］

［1］	Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha⁃reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo⁃controlled study of dutasteride versus finasteride［J］. J Am Acad Dermatol, 2006,55（6）:1014⁃1023. doi: 10.1016/j.jaad.2006.05.007.
［2］	Cong TX, Hao D, Wen X, et al. From pathogenesis of acne vulgaris to anti⁃acne agents［J］. Arch Dermatol Res, 2019,311（5）:337⁃349. doi: 10.1007/s00403⁃019⁃01908⁃x.
［3］	Azarchi S, Bienenfeld A, Lo Sicco K, et al. Androgens in women: hormone⁃modulating therapies for skin disease［J］. J Am Acad Dermatol, 2019,80（6）:1509⁃1521. doi: 10.1016/j.jaad.2018.08. 061.
［4］	Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials［J］. JAMA Dermatol, 2020,156（6）:621⁃630. doi: 10.1001/jamadermatol. 2020.0465.
［5］	Fields JR, Vonu PM, Monir RL, et al. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review［J］. Dermatol Ther, 2020,33（1）:e13202. doi: 10.1111/dth.13202.
［6］	Gupta AK, Lyons DC. The rise and fall of oral ketoconazole［J］. J Cutan Med Surg, 2015,19（4）:352⁃357. doi: 10.1177/1203475 415574970.
［7］	Santhosh P, George M. Clascoterone: a new topical anti⁃androgen for acne management［J］. Int J Dermatol，2021，60（12）:1561⁃165. doi: https://dx.doi.org/10.1111/ijd.15752.
［8］	张国毅, 林彤, 孙秋宁, 等. 口服屈螺酮炔雌醇片治疗女性中度寻常痤疮的多中心、随机、安慰剂对照临床研究［J］. 中华皮肤科杂志, 2015,48（2）:85⁃89. doi: 10.3760/cma.j.issn.0412⁃4030.2015.02.005.
［9］	Koo EB, Petersen TD, Kimball AB. Meta⁃analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris［J］. J Am Acad Dermatol, 2014,71（3）:450⁃459. doi: 10.1016/j.jaad.2014.03.051.
［10］	Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne［J］. J Am Acad Dermatol, 2018,78（2 Suppl 1）:S1⁃S23. doi: 10.1016/j.jaad. 2017.09.078.
［11］	Garg V, Choi JK, James WD, et al. Long⁃term use of spironolactone for acne in women: a case series of 403 patients［J］. J Am Acad Dermatol, 2021,84（5）:1348⁃1355. doi: 10.1016/j.jaad.2020.12.071.
［12］	Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double⁃blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia［J］. J Eur Acad Dermatol Venereol, 2018,32（12）:2257⁃2263. doi: 10.1111/jdv.15171.
［13］	Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double⁃blind, controlled study［J］. Am J Clin Dermatol, 2019,20（1）:147⁃153. doi: 10.1007/s40257⁃018⁃0387⁃0.
［14］	赵辨. 保法止®（非那雄胺片）［J］. 临床皮肤科杂志, 2002,31（5）:307⁃307. doi: 10.3969/j.issn.1000⁃4963.2002.05.021.
［15］	Lee SW, Juhasz M, Mobasher P, et al. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women［J］. J Drugs Dermatol, 2018,17（4）:457⁃463.
［16］	Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double⁃blind, placebo⁃controlled, phase III study［J］. J Am Acad Dermatol, 2010,63（2）:252⁃258. doi: 10.1016/j.jaad.2009.09.018.
［17］	Chung HC, Lee S, Lee WS. Long⁃term efficacy and safety of the dual 5⁃alpha reductase blocker dutasteride on male androgenetic alopecia patients［J］. J Dermatol, 2017,44（12）:1408⁃1409. doi: 10.1111/1346⁃8138.13710.
［18］	Vañó⁃Galván S, Saceda⁃Corralo D, Moreno⁃Arrones OM, et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study［J］. Dermatol Ther, 2020, 33（1）:e13182. doi: 10.1111/dth.13182.
［19］	Won YY, Lew BL, Sim WY. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss［J］. Dermatol Ther, 2018,31（2）:e12588. doi: 10.1111/dth.12588.
［20］	Manabe M, Tsuboi R, Itami S, et al. Guidelines for the diagnosis and treatment of male⁃pattern and female⁃pattern hair loss, 2017 version［J］. J Dermatol, 2018,45（9）:1031⁃1043. doi: 10.1111/1346⁃8138.14470.
［21］	Kanti V, Messenger A, Dobos G, et al. Evidence⁃based （S3） guideline for the treatment of androgenetic alopecia in women and in men ⁃ short version［J］. J Eur Acad Dermatol Venereol, 2018,32（1）:11⁃22. doi: 10.1111/jdv.14624.
［22］	Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss［J］. Ann Pharmacother, 2011,45（4）:469⁃475. doi: 10.1345/aph.1P600.
［23］	Fernandez⁃Nieto D, Saceda⁃Corralo D, Jimenez⁃Cauhe J, et al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss［J］. J Am Acad Dermatol, 2020,83（5）:e355⁃e356. doi: 10.1016/j.jaad.2020.04.054.
［24］	Ismail FF, Meah N, Trindade de Carvalho L, et al. Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients［J］. J Am Acad Dermatol, 2020,83（5）:1478⁃1479. doi: 10.1016/j.jaad.2020.03.034.
［25］	Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism［J］. Endocr Rev, 2000, 21（4）:347⁃362. doi: 10.1210/edrv.21.4.0401.
［26］	Tahvilian R, Ebrahimi A, Beiki O, et al. Preparation and clinical evaluation of Finastride gel in the treatment of idiopathic Hirsutism［J］. J Drug Assess, 2015,4（1）:12⁃18. doi: 10.3109/21556660.2015.1056525.
［27］	Tartagni MV, Alrasheed H, Damiani GR, et al. Intermittent low⁃dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study［J］. J Pediatr Adolesc Gynecol, 2014,27（3）:161⁃165. doi: 10.1016/j.jpag.2013.09.010.
［28］	Moretti C, Guccione L, Di Giacinto P, et al. Combined oral contraception and bicalutamide in polycystic ovary syndrome and severe hirsutism: a double⁃blind randomized controlled trial［J］. J Clin Endocrinol Metab, 2018,103（3）:824⁃838. doi: 10.1210/jc.2017⁃01186.
［29］	Gray SL, Semla TP. Post⁃finasteride syndrome［J］. BMJ, 2019,366:l5047. doi: 10.1136/bmj.l5047.
［30］	Welk B, McArthur E, Ordon M, et al. Association of suicidality and depression with 5α⁃reductase inhibitors［J］. JAMA Intern Med, 2017,177（5）:683⁃691. doi: 10.1001/jamainternmed.2017. 0089.
［31］	Wei L, Lai EC, Kao⁃Yang YH, et al. Incidence of type 2 diabetes mellitus in men receiving steroid 5α⁃reductase inhibitors: population based cohort study［J］. BMJ, 2019,365:l1204. doi: 10.1136/bmj.l1204.

[1]	Wang Wenzhu, Wang Baoxi, He Yanyan, Xu Haoxiang. Clinical phenotypes and genotypes of hidradenitis suppurativa/acne inversa [J]. Chinese Journal of Dermatology, 2023, 56(9): 892-895.
[2]	Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 885-888.
[3]	Liu Yuanxiang, Liang Yuan, Zhao Xinrong, Sun Yujuan, Ma Lin, Xu Zigang. Janus kinase inhibitors for the treatment of five children with severe alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 849-852.
[4]	Jing Ke, Wang Yuan, Li Suo, Feng Suying. Autoimmune subepidermal bullous diseases characterized by annular erythema and blisters: a retrospective analysis of 25 cases [J]. Chinese Journal of Dermatology, 2023, 56(9): 832-838.
[5]	Chen Yaolong, Liu Hui, Yao Zhirong, Gao Xinghua. Strategies and suggestions for improving the quality of guidelines and consensus in the field of dermatology [J]. Chinese Journal of Dermatology, 2023, 56(9): 805-808.
[6]	Yuan Xingang, Ni Sili, Zhang Jian, Luo Xiaoyan, Wang Hua. Improving diagnosis and treatment of melanocytic nevi in children: an urgent need [J]. Chinese Journal of Dermatology, 2023, 56(8): 782-786.
[7]	Zhong Jiemin, Shao Lei, Liang Yimin, Huang Qiongxiao, Xia Manqi, Liu Yumei. Comparative study on efficacy and safety of single microneedle radiofrequency versus photodynamic therapy in the treatment of inflammatory lesions of moderate to severe facial acne vulgaris [J]. Chinese Journal of Dermatology, 2023, 56(8): 751-755.
[8]	Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.
[9]	Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802.
[10]	Li Yue, Wu Jinyan, Yuan Ruoyue, Yang Quyang, Zhao Xiansheng, Zhu Ningwen. Cell therapy for hereditary epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2023, 56(7): 698-702.
[11]	Jia Weixue, Li Chengrang. Comparison of Chinese and international guidelines and consensus for the diagnosis and treatment of vitiligo [J]. Chinese Journal of Dermatology, 2023, 56(5): 471-475.
[12]	Li Rong, Zhang Jiaan, Chen Kun. Photoelectric therapy for rosacea [J]. Chinese Journal of Dermatology, 2023, 56(5): 468-470.
[13]	Li Jiaqi, Ye Feng, Ju Qiang. Symbiotic homeostasis of Staphylococcus epidermidis is associated with common skin disorders [J]. Chinese Journal of Dermatology, 2023, 56(5): 459-462.
[14]	Ren Fenfen, Wang Peng, Zhang Jingzhan, Kang Xiaojing. Network pharmacology-based prediction of potential effective components of traditional Chinese medicine and their molecular mechanisms of action in the anti-angiogenic treatment of Kaposi′s sarcoma [J]. Chinese Journal of Dermatology, 2023, 56(5): 428-433.
[15]	Jin Shiying, Shi Jinjun, Gao Qi, Chen Mei, Dong Zhengbang, Yan Qiao, Li Jijian, Wang Fei. High-frequency ultrasonography-assisted evaluation of treatment outcomes of erysipelas: a prospective controlled study [J]. Chinese Journal of Dermatology, 2023, 56(5): 434-438.

Anti-androgen drugs in the treatment of skin diseases

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［31］

Related Articles 15

Metrics

Comments

Recommended 10